Outlook Therapeutics CFO Kenyon acquires 101,010 shares

On August 14, 2026, Outlook Therapeutics CFO Lawrence A. Kenyon increased his ownership stake in the company by purchasing 101,010 shares of common stock. The acquisition came at a cost of $0, with each share priced at $0.0. This move was part of the company's underwritten public offering, where each share was sold alongside 1 warrant.

Kenyon's acquisition raised his direct beneficial ownership of common stock to 106,956 shares. In addition to the shares, Kenyon also acquired 101,010 warrants to purchase additional common stock at an exercise price of $1.10 per share. These warrants became exercisable immediately and were set to expire on August 14, 2031. Following the transaction, Kenyon directly held 101,010 warrants, representing the right to buy one share of Outlook Therapeutics common stock.